CHRS
Price
$0.77
Change
-$0.01 (-1.28%)
Updated
Nov 14 closing price
104 days until earnings call
DNLI
Price
$28.45
Change
-$1.18 (-3.98%)
Updated
Nov 14 closing price
108 days until earnings call
Ad is loading...

CHRS vs DNLI

Header iconCHRS vs DNLI Comparison
Open Charts CHRS vs DNLIBanner chart's image
Coherus BioSciences
Price$0.77
Change-$0.01 (-1.28%)
Volume$2.45M
CapitalizationN/A
Denali Therapeutics
Price$28.45
Change-$1.18 (-3.98%)
Volume$831.3K
CapitalizationN/A
CHRS vs DNLI Comparison Chart
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CHRS vs. DNLI commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and DNLI is a StrongSell.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (CHRS: $0.77 vs. DNLI: $28.45)
Brand notoriety: CHRS and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 87% vs. DNLI: 96%
Market capitalization -- CHRS: $89.01M vs. DNLI: $4.09B
CHRS [@Biotechnology] is valued at $89.01M. DNLI’s [@Biotechnology] market capitalization is $4.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $475.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 6 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 2 bearish.
  • DNLI’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both CHRS and DNLI are a good buy in the short-term.

Price Growth

CHRS (@Biotechnology) experienced а -5.78% price change this week, while DNLI (@Biotechnology) price change was -3.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.07%. For the same industry, the average monthly price growth was +3.27%, and the average quarterly price growth was +5.23%.

Reported Earning Dates

CHRS is expected to report earnings on Feb 27, 2025.

DNLI is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (-2.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($4.1B) has a higher market cap than CHRS($89M). DNLI YTD gains are higher at: 32.572 vs. CHRS (-76.799).
CHRSDNLICHRS / DNLI
Capitalization89M4.1B2%
EBITDAN/AN/A-
Gain YTD-76.79932.572-236%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CHRS vs DNLI: Fundamental Ratings
CHRS
DNLI
OUTLOOK RATING
1..100
558
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
10080
SMR RATING
1..100
10090
PRICE GROWTH RATING
1..100
9439
P/E GROWTH RATING
1..100
6899
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CHRS's Valuation (91) in the Biotechnology industry is in the same range as DNLI (93). This means that CHRS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Profit vs Risk Rating (80) in the Biotechnology industry is in the same range as CHRS (100). This means that DNLI’s stock grew similarly to CHRS’s over the last 12 months.

DNLI's SMR Rating (90) in the Biotechnology industry is in the same range as CHRS (100). This means that DNLI’s stock grew similarly to CHRS’s over the last 12 months.

DNLI's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for CHRS (94). This means that DNLI’s stock grew somewhat faster than CHRS’s over the last 12 months.

CHRS's P/E Growth Rating (68) in the Biotechnology industry is in the same range as DNLI (99). This means that CHRS’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSDNLI
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
78%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
View a ticker or compare two or three
Ad is loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME27.370.91
+3.44%
GameStop Corp
AAPL228.223.10
+1.38%
Apple
SPY593.35-3.84
-0.64%
SPDR® S&P 500® ETF Trust
BTC.X87250.430000-3333.734400
-3.68%
Bitcoin cryptocurrency
TSLA311.18-19.06
-5.77%
Tesla

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with PRME. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
-0.78%
PRME - CHRS
44%
Loosely correlated
-9.22%
SWTX - CHRS
40%
Loosely correlated
+5.30%
QSI - CHRS
40%
Loosely correlated
-1.52%
MGTX - CHRS
40%
Loosely correlated
-5.68%
DNLI - CHRS
39%
Loosely correlated
-3.98%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-3.98%
BEAM - DNLI
64%
Loosely correlated
-4.33%
NTLA - DNLI
58%
Loosely correlated
-6.15%
ALEC - DNLI
57%
Loosely correlated
-4.20%
JANX - DNLI
55%
Loosely correlated
-1.71%
RCKT - DNLI
53%
Loosely correlated
-5.42%
More